This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue


Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.



Dosing and administration for MENVEO

Implementing MENVEO into your practice

MENVEO can help protect your younger and older adolescent patients.

Reconstitution for MENVEO

MENVEO Dosing for Younger and Older Adolescents1
Primary Vaccination Booster Vaccination
Single dose in adolescents and adults aged 11 through 55 years Single booster dose may be administered to individuals 15 through 55 years of age who are at continued risk of meningococcal disease, at least 4 years after a prior dose of a MenACWY vaccine

Consider MENVEO for your at-risk patients as young as 2 months of age

Reconstitution for MENVEO

MENVEO Dosing for Infants1
2 Months of Age 7 Months Through 23 Months of Age
4-dose series with a single dose (0.5 mL) at 2, 4, 6, and 12 months of age 2-dose series (0.5 mL each) with the second dose administered in the second year of life, at least 3 months after the first dose

MENVEO is the only MenACWY vaccine approved for use in infants as young as 2 months of age.1-3

Reconstitution for MENVEO

Reconstitution for MENVEO

Reconstitution for MENVEO

MENVEO is a solution for intramuscular injection supplied in 2 vials, the contents of which must be combined prior to administration1:

  • MenCYW-135 liquid conjugate vaccine component (Vial 1)
  • MenA lyophilized conjugate vaccine component (Vial 2)

After reconstitution, a single dose of MENVEO is 0.5 mL.1

Please note that neither component should be given alone.

MENVEO can be reconstituted in 3 steps: PULL, MIX, and SHAKE1

PULL the entire contents of MenCYW-135 liquid (Vial 1) from the vial while slightly tilting.

MIX the MenCYW-135 liquid with the MenA conjugate (Vial 2).

INVERT the vial and shake well until powder is completely dissolved.

After reconstitution, withdraw 0.5 mL from the vial containing the reconstituted vaccine. Each dose of MENVEO should be administered as a single 0.5-mL intramuscular injection, preferably into the anterolateral aspect of the thigh in infants or into the deltoid muscle (upper arm) in toddlers, adolescents, and adults. Do not administer MENVEO intravenously, subcutaneously, or intradermally.

Watch the MENVEO preparation video

MenACWY=meningococcal serogroups A, C, W, Y.


  1. Prescribing Information for MENVEO.
  2. Prescribing Information for Menactra.
  3. Prescribing Information for MenQuadfi.


MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. MENVEO is approved for use in persons aged 2 months through 55 years. MENVEO does not prevent N. meningitidis serogroup B infections.


  • Severe allergic reaction (eg, anaphylaxis) after a previous dose of MENVEO, any component of this vaccine, or any other CRM197, diphtheria toxoid, or meningococcal-containing vaccine is a contraindication to administration of MENVEO
  • Appropriate medical treatment must be available should an acute allergic reaction, including an anaphylactic reaction, occur following administration of MENVEO
  • Syncope, sometimes resulting in falling injury associated with seizure-like movements, has been reported following vaccination with MENVEO. Vaccinees should be observed for at least 15 minutes after vaccine administration to prevent and manage syncopal reactions
  • Safety and effectiveness of MENVEO have not been evaluated in immunocompromised persons. If MENVEO is administered to immunocompromised persons, including those receiving immunosuppressive therapy, the expected immune response may not be obtained
  • Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision to administer MENVEO to subjects with a known history of GBS should take into account the potential benefits and risks
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. The decision about when to administer an intramuscular vaccine, including MENVEO, to an infant born prematurely should be based on consideration of the individual infant’s medical status and the potential benefits and possible risks of vaccination
  • In clinical trials evaluating a primary vaccination dose or series, common solicited adverse reactions with MENVEO among children initiating vaccination at 2 months of age and receiving the four-dose series were tenderness and erythema at injection site, irritability, sleepiness, persistent crying, change in eating habits, vomiting, and diarrhea. Common solicited adverse reactions among children initiating vaccination at 7 months through 23 months of age and receiving the two-dose series were tenderness and erythema at injection site, irritability, sleepiness, persistent crying, change in eating habits, and diarrhea. Common solicited adverse reactions among children aged 2 years through 10 years who received MENVEO were injection-site pain, erythema, irritability, induration, sleepiness, malaise, and headache. Common solicited adverse reactions among adolescents and adults aged 11 through 55 years who received a single dose of MENVEO were pain at the injection site, headache, myalgia, malaise, and nausea. Some events were severe. In a clinical trial evaluating booster dose vaccination among adolescents and adults aged 15 through 55 years, similar rates of solicited adverse reactions were observed following a single booster dose. Common solicited adverse reactions were pain at the injection site and fatigue
  • Vaccination with MENVEO may not result in protection in all vaccine recipients

Trademarks are property of their respective owners.